echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JCC: Vitamin D is associated with the α4β7+ immunophenotype in patients with inflammatory bowel disease and can predict the failure probability of vedolizumab treatment

    JCC: Vitamin D is associated with the α4β7+ immunophenotype in patients with inflammatory bowel disease and can predict the failure probability of vedolizumab treatment

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Integrin α4β7 is an important adhesion molecule that promotes the transport of leukocytes to the intestine, leading to intestinal inflammation


     


     


    + + +

    Figure: The relationship between α4β7 + immunophenotype and vitamin D levels

    Figure: The relationship between α4β7 + immune phenotype and vitamin D level +



    Original source:

    John Gubatan.


    Vitamin D is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.